Clinical Trial Update: Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating surufatinib in combination with toripalimab-based neoadjuvant chemo-immunotherapy and concurrent chemoradiotherapy for unresectable loc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Surufatinib (Surufatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Toripalimab, Surufatinib | Phase 2 | Status: RECRUITING